Table 4.
Cox Proportional Hazards Analysis of Overall Survival for Patients Who Received Trimodality Therapy
|
|
||||||
|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | |||||
|
| ||||||
| Variable | HR | 95% CI | p | HR | 95% CI | p |
| Age | ||||||
| ≤60 | Ref. | |||||
| >60 | 2.54 | 1.02–6.33 | 0.045 | -- | -- | -- |
| Sex | -- | -- | -- | |||
| Male | Ref. | |||||
| Female | 1.55 | 0.73–3.28 | 0.251 | -- | -- | -- |
| Masaoka-Koga Disease Stage | ||||||
| I–III | Ref. | |||||
| IVa | 2.20 | 0.99–4.89 | 0.05 | -- | -- | -- |
| Histology | ||||||
| Thymoma | Ref. | Ref. | ||||
| Thymic Carcinoma | 1.81 | 0.76–4.30 | 0.2 | 7.36 | 2.38–22.77 | 0.001 |
| Resection Status | ||||||
| R0 | Ref. | Ref. | ||||
| R1 | 1.48 | 0.66–3.34 | 0.3 | 1.24 | 0.48–3.22 | 0.7 |
| R2/Unresectable | 5.67 | 1.17–27.43 | 0.03 | 8.45 | 1.44–49.42 | 0.02 |
| ECOG Performance Status Score | ||||||
| 0 | Ref. | Ref. | ||||
| 1 | 3.85 | 1.08–13.70 | 0.04 | 8.14 | 1.55–42.75 | 0.01 |
| 2–3 | 10.49 | 2.13–51.67 | 0.004 | 29.60 | 4.0–218.98 | 0.001 |
| Diagnosis year | ||||||
| Continuous | 1.08 | 1.00–1.17 | 0.048 | -- | -- | -- |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; SUVmax, maximum standardized uptake value